Clinical trial
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in…
NCT00364026 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00364026 |
|---|---|
| Title | A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs |
| Official title | A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-201) |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | darusentan |
| Start date | Jun 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 18, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: